Tier 1: Platform Leaders
Companies with validated platforms, regulatory acceptance, and major pharma partnerships
Emulate
Human Emulation System with FDA ISTAND-qualified Liver-Chip. 87% DILI sensitivity. Wyss Institute spinout. $225M+ raised.
CN Bio Innovations
PhysioMimix multi-organ MPS platform. Liver, gut, and connected organ systems. Oxford University spinout.
TissUse
HUMIMIC multi-organ chips with integrated circulation. German engineering. Acquired by ROSEN Group 2023.
Mimetas
OrganoPlate 3-lane microfluidic platform. 96-well and 384-well formats. Membrane-free design.
Body-on-Chip & Multi-Organ Platforms
Companies building connected organ systems for systemic drug response
Hesperos
Human-on-a-Chip platform with pumpless multi-organ systems. Serum-free, self-contained circulation.
Nortis Bio
Kidney-chip and liver-chip platforms. ParVivo system for ADME-Tox. Seattle-based with academic roots.
Draper Laboratory
PREDICT96 platform for multi-tissue studies. Government and defense applications. Non-profit R&D organization.
BiomimX
uBeat platform with integrated biosensors. Italian biotech. Mechanical stimulation for cardiac models.
Organ-Specific Platform Leaders
Companies with deep expertise in specific organ models
AxoSim
Nerve-on-a-chip technology. NerveSim platform for peripheral neuropathy. New Orleans-based.
AlveoliX
Lung-on-chip with breathing mechanics. KYAN platform. Swiss biotech from University of Bern.
Altis Biosystems
RepliGut platform for intestinal models. Primary human tissue, not cell lines. Duke University spinout.
SynVivo
Blood-brain barrier chips. PREDICT-BBB platform. Photolithography-based microvascular networks.
Tara Biosystems
Biowire platform for cardiac tissue. Acquired by Valo Health 2021. hiPSC-derived cardiomyocytes.
Nortis Bio
Kidney proximal tubule and liver models. ParVivo perfusion system. University of Washington spinout.
Rising Innovators
Early-stage companies with innovative approaches and breakthrough technology
Aracari Biosciences
VascuLab platform. Vascularized tissue models with perfusable microvessels. California startup.
Cherry Biotech
CUBO temperature control for organ-chips. French biotech. Platform-agnostic technology.
Javelin Biotech
Multiplexed organ-chip systems. MIT spinout. Single-cell resolution analytics.
Bi/ond
Dynamic organ-on-chip with real-time sensing. Dutch biotech. Eindhoven University of Technology spinout.
Sector Analysis
Market Overview
- + Organ-on-chip market projected to reach $1.8B by 2030 (23% CAGR)
- + FDA Modernization Act 2.0 (2022) enables regulatory acceptance
- + First FDA ISTAND qualification achieved September 2024 (Emulate)
- + Major pharma partnerships with all top 20 pharmaceutical companies
- + Growing adoption for DILI, nephrotoxicity, and CNS penetration studies
Key Applications
Drug-induced liver injury screening. 87% sensitivity demonstrated.
Absorption, distribution, metabolism, excretion, and toxicity.
Blood-brain barrier permeability for CNS drug candidates.
Disease modeling for target validation and mechanism studies.
Explore More Categories
Discover companies across all human-relevant technology sectors